Sector News

Cambrex makes $25 million deal

September 27, 2016
Life sciences

East Rutherford-based life sciences company Cambrex Corp. has agreed to buy a North Carolina-based drug company to expand its pharmaceutical ingredients business.

Cambrex will pay about $25 million for High Point, N.C.-based PharmaCore Inc., a privately owned provider of small molecule active pharmaceutical ingredients for clinical projects.

The deal, expected to be completed within 30 days, was announced Monday by the two companies in a joint statement.

PharmaCore, which generates $15 million to $17 million in annual revenue, was founded 1999, and it employs more than 60 people, including nearly 40 process and analytical chemists.

By Richard Newman

Source: NorthJersey.com

Related News

September 23, 2020

Novartis, Siemens to develop blood tests for multiple sclerosis

Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the companies […]

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]